NCT00559195

Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors

Phase 2 Study Evaluating the Efficacy of Epoetin Beta (Neocormon®) For Fatigue and Quality of Life of Patients Receiving Palliative Care for a Solid Malignant Tumor

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Centre Hospital Regional Universitaire de Limoges · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Epoetin beta may cause the body to make more red blood cells and may help relieve fatigue in patients with malignant solid tumors receiving palliative care. PURPOSE: This phase II trial is studying how well epoetin beta works in treating fatigue and anemia in patients receiving palliative care for malignant solid tumors.

Detailed description

OBJECTIVES: Primary * Evaluate the impact of epoetin beta on fatigue and quality of life of patients receiving palliative care for malignant solid tumors. Secondary * Evaluate the impact of epoetin beta on hemoglobin level (increase \> 2 g/dL). OUTLINE: Patients receive epoetin beta subcutaneously once a week for up to 3 months. Fatigue, quality of life, and hemoglobin and reticulocyte levels are assessed every 4 weeks.

Conditions

• Anemia
• Fatigue
• Unspecified Adult Solid Tumor, Protocol Specific

Interventions

Type	Name	Description
BIOLOGICAL	epoetin beta
PROCEDURE	quality-of-life assessment

Timeline

• Start date: 2005-11-01
• Primary completion: 2011-05-01
• First posted: 2007-11-16
• Last updated: 2011-05-16

Locations

1 site across 1 country: France